Show simple item record

dc.contributor.authorMartin-Geary, Alexandra C.
dc.contributor.authorBlakes, Alexander J.
dc.contributor.authorDawes, Ruebena
dc.contributor.authorFindlay, Scott D.
dc.contributor.authorLord, Jenny
dc.contributor.authorDong, Shan
dc.contributor.authorWalker, Susan
dc.contributor.authorTalbot-Martin, Jonathan
dc.contributor.authorWieder, Nechama
dc.contributor.authorD’Souza, Elston N.
dc.contributor.authorFernandes, Maria
dc.contributor.authorHilton, Sarah
dc.contributor.authorLahiri, Nayana
dc.contributor.authorCampbell, Christopher
dc.date.accessioned2025-08-13T16:40:39Z
dc.date.available2025-08-13T16:40:39Z
dc.date.issued2025-04-14
dc.identifier.urihttps://hdl.handle.net/1721.1/162365
dc.description.abstractBackground Both promoters and untranslated regions (UTRs) have critical regulatory roles, yet variants in these regions are largely excluded from clinical genetic testing due to difficulty in interpreting pathogenicity. The extent to which these regions may harbour diagnoses for individuals with rare disease is currently unknown. Methods We present a framework for the identification and annotation of potentially deleterious proximal promoter and UTR variants in known dominant disease genes. We use this framework to annotate de novo variants (DNVs) in 8040 undiagnosed individuals in the Genomics England 100,000 genomes project, which were subject to strict region-based filtering, clinical review, and validation studies where possible. In addition, we performed region and variant annotation-based burden testing in 7862 unrelated probands against matched unaffected controls. Results We prioritised eleven DNVs and identified an additional variant overlapping one of the eleven. Ten of these twelve variants (82%) are in genes that are a strong match to the individual’s phenotype and six had not previously been identified. Through burden testing, we did not observe a significant enrichment of potentially deleterious promoter and/or UTR variants in individuals with rare disease collectively across any of our region or variant annotations. Conclusions Whilst screening promoters and UTRs can uncover additional diagnoses for individuals with rare disease, including these regions in diagnostic pipelines is not likely to dramatically increase diagnostic yield. Nevertheless, we provide a framework to aid identification of these variants.en_US
dc.publisherBioMed Centralen_US
dc.relation.isversionofhttps://doi.org/10.1186/s13073-025-01464-2en_US
dc.rightsCreative Commons Attributionen_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_US
dc.sourceBioMed Centralen_US
dc.titleSystematic identification of disease-causing promoter and untranslated region variants in 8040 undiagnosed individuals with rare diseaseen_US
dc.typeArticleen_US
dc.identifier.citationMartin-Geary, A.C., Blakes, A.J., Dawes, R. et al. Systematic identification of disease-causing promoter and untranslated region variants in 8040 undiagnosed individuals with rare disease. Genome Med 17, 40 (2025).en_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biologyen_US
dc.relation.journalGenome Medicineen_US
dc.identifier.mitlicensePUBLISHER_CC
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2025-07-18T15:34:36Z
dc.language.rfc3066en
dc.rights.holderCrown
dspace.date.submission2025-07-18T15:34:36Z
mit.journal.volume17en_US
mit.licensePUBLISHER_CC
mit.metadata.statusAuthority Work and Publication Information Neededen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record